BACKGROUND: Hypertension is an established risk factor for acute coronary events. Because fibrinolytic and hemostatic factors are also associated with cardiovascular disease, we examined the relations of systolic and diastolic blood pressures (SBP and DBP) to levels of plasminogen activator inhibitor antigen, tissue plasminogen activator antigen, fibrinogen, factor VII, von Willebrand factor, fibrinogen, and plasma viscosity in subjects of the Framingham Offspring Study. METHODS AND RESULTS: We studied 1193 men and 1459 women after the exclusion of subjects with known cardiovascular disease and those receiving anticoagulant or antihypertensive therapy. Linear regression models were used to evaluate SBP and DBP as predictors of fibrinolytic and hemostatic factor levels in separate sex models, with adjustment for age, body mass index, smoking, diabetes, total cholesterol, HDL, triglycerides, alcohol intake, and estrogen use (in women). In both sexes, levels of plasminogen activator inhibitor and tissue plasminogen activator antigen were positively related to SBP and DBP (P<0.001). Plasma viscosity was positively related to SBP (P=0.008) and DBP (P=0.001) in women only. There was no association between SBP or DBP and fibrinogen, factor VII, or von Willebrand factor in either sex. CONCLUSIONS: These data suggest that impaired fibrinolysis may play an important role in the pathogenesis of cardiovascular disease in hypertensive patients.
BACKGROUND:Hypertension is an established risk factor for acute coronary events. Because fibrinolytic and hemostatic factors are also associated with cardiovascular disease, we examined the relations of systolic and diastolic blood pressures (SBP and DBP) to levels of plasminogen activator inhibitor antigen, tissue plasminogen activator antigen, fibrinogen, factor VII, von Willebrand factor, fibrinogen, and plasma viscosity in subjects of the Framingham Offspring Study. METHODS AND RESULTS: We studied 1193 men and 1459 women after the exclusion of subjects with known cardiovascular disease and those receiving anticoagulant or antihypertensive therapy. Linear regression models were used to evaluate SBP and DBP as predictors of fibrinolytic and hemostatic factor levels in separate sex models, with adjustment for age, body mass index, smoking, diabetes, total cholesterol, HDL, triglycerides, alcohol intake, and estrogen use (in women). In both sexes, levels of plasminogen activator inhibitor and tissue plasminogen activator antigen were positively related to SBP and DBP (P<0.001). Plasma viscosity was positively related to SBP (P=0.008) and DBP (P=0.001) in women only. There was no association between SBP or DBP and fibrinogen, factor VII, or von Willebrand factor in either sex. CONCLUSIONS: These data suggest that impaired fibrinolysis may play an important role in the pathogenesis of cardiovascular disease in hypertensivepatients.
Authors: A M Wägner; J C Wiebe; M Boronat; P Saavedra; D Marrero; F Varillas; F J Nóvoa Journal: J Endocrinol Invest Date: 2010-10-27 Impact factor: 4.256
Authors: J A Schoenhard; F W Asselbergs; K A Poku; S A Stocki; S Gordon; D E Vaughan; N J Brown; J H Moore; Scott M Williams Journal: Hum Genet Date: 2008-10-25 Impact factor: 4.132
Authors: Mercedes Sotos-Prieto; Marisa Guillén; Olga Portolés; José V Sorlí; José I González; Eva M Asensio; Dolores Corella Journal: Genes Nutr Date: 2012-12-09 Impact factor: 5.523
Authors: Wolfgang Lieb; Michael J Pencina; Thomas J Wang; Martin G Larson; Katherine J Lanier; Emelia J Benjamin; Daniel Levy; Geoffrey H Tofler; James B Meigs; Christopher Newton-Cheh; Ramachandran S Vasan Journal: Hypertension Date: 2008-06-23 Impact factor: 10.190
Authors: Sandrine Delbosc; Mounsif Haloui; Liliane Louedec; Morgan Dupuis; Myriam Cubizolles; Vladimir N Podust; Eric T Fung; Jean-Baptiste Michel; Olivier Meilhac Journal: Mol Med Date: 2008 Jul-Aug Impact factor: 6.354